Propeptide and VWF antigen levels and activity of ADAMTS13
| . | LAC positive due to anti–β2GPI antibodies . | LAC positive due to antiprothrombin antibodies . | LAC-negative SLE patients . |
|---|---|---|---|
| VWF antigen, μg/mL | 23.4 ± 9.4 | 18.3 ± 4.5 | 22.1 ± 9.1 |
| VWF propeptide, μg/mL | 0.17 ± 0.10 | 0.13 ± 0.05 | 0.16 ± 0.14 |
| Propeptide/mature VWF, mol/mol | 0.09 ± 0.03 | 0.09 ± 0.03 | 0.08 ± 0.02 |
| ADAMTS13 activity, % | 81.7 ± 28.5 | 71.7 ± 31.1 | 66.5 ± 20.8 |
| . | LAC positive due to anti–β2GPI antibodies . | LAC positive due to antiprothrombin antibodies . | LAC-negative SLE patients . |
|---|---|---|---|
| VWF antigen, μg/mL | 23.4 ± 9.4 | 18.3 ± 4.5 | 22.1 ± 9.1 |
| VWF propeptide, μg/mL | 0.17 ± 0.10 | 0.13 ± 0.05 | 0.16 ± 0.14 |
| Propeptide/mature VWF, mol/mol | 0.09 ± 0.03 | 0.09 ± 0.03 | 0.08 ± 0.02 |
| ADAMTS13 activity, % | 81.7 ± 28.5 | 71.7 ± 31.1 | 66.5 ± 20.8 |
All data represent mean (± SD), n = 10. Normal ranges are as follows: VWF antigen, 6.1-14.2 μg/mL; VWF propeptide, 0.6-1.6 μg/mL; propeptide/mature VWF ratio, 0.04-0.21; and ADAMTS13 activity, 61%-142 %.